Concepedia

Satyajit Rajapurkar

SR

Statistics

Publications

6

Citations

653

H-Index

6

Active since

2015

Affiliations

GlaxoSmithKline (United States)(Current)

University of Pennsylvania

Target (United States)

Satyajit Rajapurkar is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and molecular oncology.

Publications per year

2015–2022

6

Publications

6

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacology +7

Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo

Raymond E. Soccio, Eric R. Chen, Satyajit Rajapurkar et al. · Cell · 2015 · 123 citations · Full text

Medicine, Genetics, Molecular Genetics +11

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes

Kimberly N. Smitheman, Tesa Severson, Satyajit Rajapurkar et al. · Haematologica · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting PPARγ in the epigenome rescues genetic metabolic defects in mice

Raymond E. Soccio, Zhenghui Li, Eric R. Chen et al. · Journal of Clinical Investigation · 2017 · 54 citations · Full text

Medicine, Genetics, Pharmacology +17

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Anastasia Wyce, Jeanne J. Matteo, Shawn W. Foley et al. · Oncogenesis · 2018 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 6